Takeda’s Maribavir Post-Transplant CMV Indication Should Not Be Limited By Resistance, US Panel Says

 
• By Sue Sutter
Slam dunk
Despite reservations about the pivotal trial, an FDA panel's vote for Takeda's maribavir was a slam dunk. • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers